Wallaby/phenox officially announces global launch of Pegasus HPC stent system

1608

Wallaby/phenox has officially announced the successful global launch of its novel Pegasus hydrophilic polymer coating (HPC) stent, having first unveiled the device at the 2022 European Society of Minimally Invasive Neurological Therapy (ESMINT) congress (7–9 September, Nice, France).

The introduction of the Pegasus stent enables more patients to benefit from the company’s HPC surface modification in stent-assisted coiling treatments, as well as intracranial atherosclerotic disease (ICAD) and dissections. The application of this surface modification to the stent results in enhanced safety by significantly reducing thrombogenic complications, a Wallaby/phenox press release states.

“The benefits offered by surface modification are exceptional and similar to those in flow diverter devices such as the p64 MW HPC [Wallaby/phenox],” said Markus Holtmannspötter (Klinikum Nuremberg, Nuremberg, Germany). “HPC enables us to use single antiplatelet therapy in selected cases per IFU [instructions for use] and in turn reduces haemorrhagic complications.”

According to Wallaby/phenox, the Pegasus HPC stent is the first stent of its kind to introduce coating technology for the treatment of ICAD and aneurysms. Thus, the device addresses multiple indications while providing all the benefits of classic laser-cut, open-cell stents and adding increased patient safety.

The stent is compatible with 0.0165-inch or 0.017-inch inner diameter (ID) catheters, enabling access to distal lesions. The uniform cell design allows easy crossing and dense coiling without the need for additional microcatheters, and its unique open-cell structure guarantees flexibility and advanced kink resistance to ensure good wall apposition—even in tortuous anatomy—the release adds.

“With the introduction of the Pegasus HPC, Wallaby/phenox is committed more than ever to being the driving force of innovation in the neurovascular field,” said Wallaby CEO Michael Alper. “We will continue providing doctors with solutions that lead to the best possible outcome for the patient.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here